Goldwind Science & Technology (02208) shareholder China Three Gorges Renewables reduces its holding by approximately 6.769 million shares.
Goldenwind Technology (02208) announced that on March 2, 2026, the company received a notification letter from its shareholder China Three Gorges New Energy (Group) Co., Ltd., regarding the reduction of shares reaching a multiple of 1%. Three Gorges Energy reduced its shareholding in the company by approximately 6.7689 million shares through centralized bidding from January 19, 2026 to March 2, 2026, representing 0.160257% of the total share capital of the company. After this equity change, Three Gorges Energy's shareholding in the company decreased from approximately 387 million shares to approximately 380 million shares, and its percentage of total share capital decreased from 9.160252% to 8.999995%, reaching a multiple of 1% of equity change.
Goldwind Science & Technology (02208) announced that on March 2, 2026, the company received a notice from shareholder China Three Gorges New Energy (Group) Co., Ltd. regarding the reduction of shareholding reaching a multiple of 1%. From January 19, 2026, to March 2, 2026, China Three Gorges Renewables reduced its stake in the company by approximately 6.7689 million shares through centralized bidding, representing 0.160257% of the company's total share capital. After this equity change, China Three Gorges Renewables' holdings in the company decreased from approximately 387 million shares to approximately 380 million shares, reducing its proportion of total share capital from 9.160252% to 8.999995%, with the equity change reaching a multiple of 1%.
Related Articles
RIMAG GROUP (02522): Liu Senlin resigns as non-executive director.
Xd Inc (02400) spent HK$7.8857 million to repurchase 108,000 shares on March 3.
Kexing Biopharm (688136.SH): GB19 Injection for the treatment of skin lupus erythematosus indications received approval notice for drug clinical trials.
RIMAG GROUP (02522): Liu Senlin resigns as non-executive director.
Xd Inc (02400) spent HK$7.8857 million to repurchase 108,000 shares on March 3.
Kexing Biopharm (688136.SH): GB19 Injection for the treatment of skin lupus erythematosus indications received approval notice for drug clinical trials.
RECOMMEND
